HK1094891A1 - Compounds for treatment of cell proliferative diseases - Google Patents

Compounds for treatment of cell proliferative diseases

Info

Publication number
HK1094891A1
HK1094891A1 HK07102345.1A HK07102345A HK1094891A1 HK 1094891 A1 HK1094891 A1 HK 1094891A1 HK 07102345 A HK07102345 A HK 07102345A HK 1094891 A1 HK1094891 A1 HK 1094891A1
Authority
HK
Hong Kong
Prior art keywords
compounds
treatment
cell proliferative
proliferative diseases
diseases
Prior art date
Application number
HK07102345.1A
Other languages
English (en)
Inventor
Waldemar Priebe
Nicholas Donato
Moshe Talpaz
Slawomir Szymanski
Izabela Fokt
Alexander Levitki
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of HK1094891A1 publication Critical patent/HK1094891A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK07102345.1A 2003-12-11 2007-03-02 Compounds for treatment of cell proliferative diseases HK1094891A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52887703P 2003-12-11 2003-12-11
PCT/US2004/041712 WO2005058829A1 (fr) 2003-12-11 2004-12-13 Composes pour traiter des maladies associees a une proliferation cellulaire

Publications (1)

Publication Number Publication Date
HK1094891A1 true HK1094891A1 (en) 2007-04-13

Family

ID=34699909

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07102345.1A HK1094891A1 (en) 2003-12-11 2007-03-02 Compounds for treatment of cell proliferative diseases

Country Status (18)

Country Link
US (4) US7745468B2 (fr)
EP (2) EP1701941B1 (fr)
JP (1) JP4751336B2 (fr)
KR (2) KR101170655B1 (fr)
CN (2) CN102603565A (fr)
AU (1) AU2004298511B2 (fr)
BR (1) BRPI0416981A (fr)
CA (1) CA2548152C (fr)
DK (1) DK1701941T3 (fr)
ES (1) ES2385831T3 (fr)
HK (1) HK1094891A1 (fr)
IL (1) IL176028A (fr)
MX (1) MXPA06006460A (fr)
PL (1) PL1701941T3 (fr)
PT (1) PT1701941E (fr)
SI (1) SI1701941T1 (fr)
WO (1) WO2005058829A1 (fr)
ZA (1) ZA200604682B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603565A (zh) 2003-12-11 2012-07-25 得克萨斯州大学系统董事会 治疗细胞增殖疾病的化合物
EP1945612A2 (fr) 2005-10-13 2008-07-23 Orchid Research Laboratories Limited Nouveaux composes heterocycliques en tant qu'inhibiteurs de pstat3/il6
RU2456265C2 (ru) * 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
WO2008005954A2 (fr) * 2006-06-30 2008-01-10 The Board Of Regents Of The University Of Texas System Modulateurs de protéine signal en tant qu'agents thérapeutiques
WO2008063603A2 (fr) 2006-11-20 2008-05-29 President And Fellows Of Harvard College Méthodes, compositions et trousses destinés au traitement de la douleur et du prurit
WO2008083389A1 (fr) * 2006-12-29 2008-07-10 Moleculin, L.L.C. Procédés de traitement de troubles de la peau avec des analogues de l'acide caféique
WO2008121858A1 (fr) * 2007-03-28 2008-10-09 Board Of Regents, The University Of Texas System Inhibiteurs de type petite molécule, pour la modulation immune
US9732055B2 (en) 2007-09-10 2017-08-15 Boston Biomedical, Inc. Compositions and methods for cancer treatment
EA020766B1 (ru) * 2008-07-08 2015-01-30 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
CA2738786C (fr) 2008-09-30 2017-12-19 Mallinckrodt Inc. Version de fdg detectable par tomographie par emission a photon unique
US8450337B2 (en) * 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US20120021941A1 (en) * 2009-01-12 2012-01-26 The Board Of Regents Of The University Of Texas System Blood test for the detection of cancer
CA2767646C (fr) 2009-07-10 2019-01-29 President And Fellows Of Harvard College Bloqueurs de canaux sodiques et calciques charges de maniere permanente comme agents anti-inflammatoires
CN102695699B (zh) 2009-10-16 2016-02-24 拜耳知识产权有限责任公司 作为杀菌剂的氨基丙烯酸酯
WO2011069141A2 (fr) 2009-12-04 2011-06-09 Board Of Regents, The University Of Texas System Traitement à l'interféron en combinaison avec un blocage de l'activation de stat3
US9155724B2 (en) 2010-02-05 2015-10-13 Whitehead Institute For Biomedical Research Combination methods for treatment of disease
DK2547205T3 (da) 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
EP2619184B1 (fr) * 2010-09-24 2018-05-23 The Regents of the University of Michigan Inhibiteurs de déubiquitinase et leurs procédés d'utilisation
EP2510787A1 (fr) 2011-04-15 2012-10-17 Bayer Cropscience AG Propènoates en tant que fongicides
JPWO2012165262A1 (ja) 2011-05-27 2015-02-23 国立大学法人徳島大学 ベンジルアミン誘導体
EP2731493B1 (fr) 2011-07-11 2015-07-01 The Regents of The University of Michigan Dispositif multimodalité d'occlusion de l'appendice de l'auricule gauche
WO2013177534A2 (fr) * 2012-05-25 2013-11-28 The Governing Council Of The University Of Toronto Nouveaux dérivés d'acide salicylique, sel de qualité pharmaceutique correspondant, composition et procédé d'utilisation correspondants
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
RU2015147696A (ru) 2013-04-09 2017-05-12 Бостон Байомедикал, Инк. Способы лечения злокачественной опухоли
WO2015002766A1 (fr) * 2013-07-02 2015-01-08 Nikolai Khodarev Thérapie anti-tumorale
CA2927023C (fr) * 2013-10-10 2022-08-02 The Regents Of The University Of Michigan Inhibiteurs de deubiquitinase et methodes d'utilisation de ceux-ci
EP3212773B1 (fr) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Administration efficace de molécules thérapeutiques en direction de cellules de l'oreille interne
KR20180069782A (ko) 2015-08-03 2018-06-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 하전 이온 채널 블록커 및 이용 방법
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (fr) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methodes pour le traitement du cancer
KR20200085815A (ko) 2017-11-10 2020-07-15 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 과증식성 질병의 치료를 위한 카페인산 유도체
EP3743057A4 (fr) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary Traitement de la perte auditive
JP2022527731A (ja) 2019-03-11 2022-06-06 ノシオン セラピューティクス，インコーポレイテッド エステル置換イオンチャンネル遮断薬および使用方法
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP3937945A4 (fr) 2019-03-11 2023-01-04 Nocion Therapeutics, Inc. Bloqueurs de canaux ioniques chargés et procédés d'utilisation
JP2022527438A (ja) 2019-03-11 2022-06-02 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
CA3135844A1 (fr) * 2019-04-02 2020-10-08 Board Of Regents, The University Of Texas System Combinaisons d'inhibiteurs de transcription et d'inhibiteurs de point de controle immunitaire pour traiter une maladie
WO2020206424A1 (fr) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Agents de dégradation de stat et leurs utilisations
JP7513713B2 (ja) 2019-11-06 2024-07-09 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
BR112022008575A2 (pt) 2019-11-06 2022-08-09 Nocion Therapeutics Inc Bloqueadores de canal iônico carregado e métodos para uso
CN115279731A (zh) 2020-03-11 2022-11-01 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
CN115381822A (zh) * 2022-05-11 2022-11-25 暨南大学附属第一医院（广州华侨医院） 一种基于激活免疫应答治疗肺癌的药物及制药应用
KR20230175010A (ko) * 2022-06-22 2023-12-29 한국생명공학연구원 신규한 신남아마이드 유도체 및 이의 용도

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2555789A1 (de) * 1975-12-11 1977-07-07 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
FR2629455B1 (fr) * 1988-03-29 1991-09-27 Rhone Poulenc Agrochimie Derives de 2-(3-pyridinyl)3-(phenoxy) propanenitrile
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
AU662480B2 (en) 1990-04-16 1995-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
CA2080554A1 (fr) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Derives du styrene
CA2092017A1 (fr) 1992-03-26 1993-09-27 Tameo Iwasaki Derives de butadiene et procedes pour leur obtention
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH06247850A (ja) 1993-02-24 1994-09-06 Suntory Ltd １２−リポキシゲナーゼ阻害剤
US5823706A (en) 1993-07-27 1998-10-20 The University Of Birmingham Pavements
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
IL107736A (en) 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
IL112205A0 (en) 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
IL113444A0 (en) 1994-04-22 1995-07-31 Roifman Chaim Compositions and methods for treating leukemia
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
US5854285A (en) 1997-04-03 1998-12-29 Natpro, Inc. Protein kinase inhibitor
US6420338B1 (en) 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
EP1000935A4 (fr) * 1997-07-25 2001-03-21 Tsumura & Co Derives de pyridylacrylamide, remedes contre la nephrite et inhibiteurs de tgf-beta contenant lesdits elements
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
WO2000052062A1 (fr) 1999-03-04 2000-09-08 Riken Composition de catalyseur
US20020045191A1 (en) 2000-09-15 2002-04-18 Schneider Robert J. Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
JP2003119169A (ja) 2001-07-30 2003-04-23 Shigetoshi Kadota 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
EP1457205A4 (fr) 2001-11-30 2006-07-05 Santen Pharmaceutical Co Ltd Inhibiteur d'angiogenese
WO2003068157A2 (fr) 2002-02-11 2003-08-21 The Brigham And Women's Hospital, Inc. Inhibiteurs de kinase et leurs procedes d'utilisation
WO2004047743A2 (fr) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyle amides ouvreurs de canaux potassiques
KR20050055479A (ko) 2003-12-08 2005-06-13 김철호 카페인산 또는 카페인산 페네틸에스테르를 유효성분으로하는 ｍｍｐ-9 억제제
CN102603565A (zh) * 2003-12-11 2012-07-25 得克萨斯州大学系统董事会 治疗细胞增殖疾病的化合物
RU2456265C2 (ru) * 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
WO2008005954A2 (fr) 2006-06-30 2008-01-10 The Board Of Regents Of The University Of Texas System Modulateurs de protéine signal en tant qu'agents thérapeutiques
EP2104424A4 (fr) * 2006-10-30 2011-06-15 Wockhardt Research Center Compositions pharmaceutiques comprenant l'entacapone, la lévodopa, et la carbidopa

Also Published As

Publication number Publication date
IL176028A0 (en) 2006-10-05
CN1894215A (zh) 2007-01-10
JP4751336B2 (ja) 2011-08-17
MXPA06006460A (es) 2006-08-23
CA2548152C (fr) 2013-09-10
US8119827B2 (en) 2012-02-21
KR20070000428A (ko) 2007-01-02
KR101170655B1 (ko) 2012-08-03
EP1701941A4 (fr) 2008-11-12
EP2487156B1 (fr) 2014-07-16
US8648102B2 (en) 2014-02-11
US20120214850A1 (en) 2012-08-23
US9096499B2 (en) 2015-08-04
SI1701941T1 (sl) 2012-09-28
US20050277680A1 (en) 2005-12-15
BRPI0416981A (pt) 2007-02-21
KR101218633B1 (ko) 2013-01-09
CN102603565A (zh) 2012-07-25
US7745468B2 (en) 2010-06-29
JP2007515413A (ja) 2007-06-14
US20140329901A1 (en) 2014-11-06
IL176028A (en) 2012-05-31
CN1894215B (zh) 2012-03-21
EP2487156A1 (fr) 2012-08-15
KR20110132489A (ko) 2011-12-07
EP1701941A1 (fr) 2006-09-20
AU2004298511A1 (en) 2005-06-30
EP1701941B1 (fr) 2012-05-30
DK1701941T3 (da) 2012-08-13
ES2385831T3 (es) 2012-08-01
CA2548152A1 (fr) 2005-06-30
AU2004298511B2 (en) 2011-08-11
PT1701941E (pt) 2012-08-03
WO2005058829A1 (fr) 2005-06-30
ZA200604682B (en) 2008-04-30
US20110021805A1 (en) 2011-01-27
PL1701941T3 (pl) 2012-11-30

Similar Documents

Publication Publication Date Title
IL176028A0 (en) Compounds for treatment of cell proliferative diseases
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
EP1804794A4 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
HK1204476A1 (en) Compounds and methods for treatment of cancer
ZA200508427B (en) Methods for treating interleuking-6 related diseases
IL172346A0 (en) Treatment of t cell mediated diseases by inhibition of fgfr3
IL178860A (en) Certain chemical entities, preparations and processes
EP1613308A4 (fr) Procedes de traitement du cancer
HK1079106A1 (en) Composition for treating hyperproliferative diseases
IL181305A0 (en) Combinations for the treatment of diseases involving cell proliferation
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
GB0329874D0 (en) Compounds useful for the treatment of diseases
SI1685125T1 (sl) Derivati pirola, primerni za zdravljenje proliferativnih bolezni
PL1801108T3 (pl) Związki morfolinowe do leczenia stanów zapalnych
GB0305150D0 (en) Use of therapeutic compounds
EP1611120A4 (fr) Nouvelles m thodes de traitement des maladies inflammatoires
EP1651237A4 (fr) Methodes de traitement de troubles dermatologiques
EP1709155A4 (fr) Composes et compositions destines au traitement de maladies dysplasiques, et leurs methodes d'utilisation
PT1742937E (pt) Derivados de pirrolopirimidina úteis para o tratamento de doenças proliferativas
GB0400802D0 (en) Compounds for the treatment of disease
ZA200606780B (en) Compounds for the treatment of diseases
IL175611A0 (en) Combinations for the treatment of proliferative diseases
AP2006003728A0 (en) Compounds for treatment of diseases
SI1535612T1 (sl) Zdravljenje hiperurikemije
GB0425073D0 (en) Compounds for the treatment of diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161213